Mucosal α4β7+ Lymphocytes and MAdCAM+ Venules Predict Response to Vedolizumab in Ulcerative Colitis

Area of Science:

• Gastroenterology
• Immunology
• Molecular Medicine

Background:

• Current ulcerative colitis (UC) treatment strategies lack predictive power for individual patient outcomes.
• A significant portion of UC patients do not respond to vedolizumab, highlighting the need for pretreatment biomarkers.
• Mucosal markers associated with T lymphocyte homing present potential predictive capabilities.

Purpose of the Study:

• To identify pretreatment biomarkers for predicting therapeutic efficacy of vedolizumab in UC patients.
• To evaluate the role of mucosal markers, specifically α4β7 and MAdCAM-1, as predictors of vedolizumab response.

Main Methods:

• Prospective study of 21 biological- and steroid-naive UC patients undergoing vedolizumab therapy.
• Immunophenotyping and immunohistochemistry of colonic biopsies at baseline (week 0).
• Assessment of clinical and endoscopic disease activity at week 16 post-treatment.

Main Results:

• Baseline abundance of α4β7 on CD3+ T lymphocytes (>8%) predicted vedolizumab responsiveness with 100% sensitivity and specificity.
• MAdCAM-1+ venules (≥2.59%) also showed high predictive value (89% sensitivity, 100% specificity).
• Responders showed a significant decrease in α4β7+CD3+ T lymphocytes post-treatment, unlike non-responders.

Conclusions:

• Elevated α4β7+CD3+ T lymphocytes and MAdCAM-1+ venules in baseline UC biopsies are promising predictive biomarkers for vedolizumab response.
• These biomarkers may facilitate more personalized treatment approaches for ulcerative colitis patients.